673 related articles for article (PubMed ID: 8033152)
1. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
[TBL] [Abstract][Full Text] [Related]
2. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
Libè R; Groussin L; Tissier F; Elie C; René-Corail F; Fratticci A; Jullian E; Beck-Peccoz P; Bertagna X; Gicquel C; Bertherat J
Clin Cancer Res; 2007 Feb; 13(3):844-50. PubMed ID: 17289876
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas.
Saxena A; Clark WC; Robertson JT; Ikejiri B; Oldfield EH; Ali IU
Cancer Res; 1992 Dec; 52(23):6716-21. PubMed ID: 1358438
[TBL] [Abstract][Full Text] [Related]
4. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
6. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma.
Nishida N; Fukuda Y; Kokuryu H; Toguchida J; Yandell DW; Ikenega M; Imura H; Ishizaki K
Cancer Res; 1993 Jan; 53(2):368-72. PubMed ID: 8093350
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
8. Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers.
Konishi H; Takahashi T; Kozaki K; Yatabe Y; Mitsudomi T; Fujii Y; Sugiura T; Matsuda H; Takahashi T; Takahashi T
Oncogene; 1998 Oct; 17(16):2095-100. PubMed ID: 9798680
[TBL] [Abstract][Full Text] [Related]
9. A region close to Tp53 shows LOH in familial breast cancer.
Luo L; Chen J; Du Q; Dumanski J; Blennow E; Kockum I; Luthman H; Lindblom A
Int J Mol Med; 2002 Apr; 9(4):405-9. PubMed ID: 11891537
[TBL] [Abstract][Full Text] [Related]
10. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters.
Seitz S; Poppe K; Fischer J; Nothnagel A; Estévez-Schwarz L; Haensch W; Schlag PM; Scherneck S
J Pathol; 2001 Jul; 194(3):318-26. PubMed ID: 11439364
[TBL] [Abstract][Full Text] [Related]
11. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus.
Okamoto A; Sameshima Y; Yamada Y; Teshima S; Terashima Y; Terada M; Yokota J
Cancer Res; 1991 Oct; 51(20):5632-5. PubMed ID: 1913680
[TBL] [Abstract][Full Text] [Related]
12. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius S; Börresen AL; Eyfjörd JE
Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas.
Yamaguchi T; Toguchida J; Wadayama B; Kanoe H; Nakayama T; Ishizaki K; Ikenaga M; Kotoura Y; Sasaki MS
Anticancer Res; 1996; 16(4A):2009-15. PubMed ID: 8712735
[TBL] [Abstract][Full Text] [Related]
14. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
15. The relationship between allelic imbalance on 17p, p53 mutation and p53 overexpression in head and neck cancer.
Götte K; Riedel F; Neubauer J; Schäfer C; Coy JF; Hörmann K
Int J Oncol; 2001 Aug; 19(2):331-6. PubMed ID: 11445847
[TBL] [Abstract][Full Text] [Related]
16. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
17. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas.
Wagata T; Shibagaki I; Imamura M; Shimada Y; Toguchida J; Yandell DW; Ikenaga M; Tobe T; Ishizaki K
Cancer Res; 1993 Feb; 53(4):846-50. PubMed ID: 8094033
[TBL] [Abstract][Full Text] [Related]
18. Allelotype analysis of esophageal squamous cell carcinoma.
Shibagaki I; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
Cancer Res; 1994 Jun; 54(11):2996-3000. PubMed ID: 8187088
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity and p53 gene mutations in breast cancer.
Deng G; Chen LC; Schott DR; Thor A; Bhargava V; Ljung BM; Chew K; Smith HS
Cancer Res; 1994 Jan; 54(2):499-505. PubMed ID: 8275488
[TBL] [Abstract][Full Text] [Related]
20. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions.
Negrini M; Sabbioni S; Haldar S; Possati L; Castagnoli A; Corallini A; Barbanti-Brodano G; Croce CM
Cancer Res; 1994 Apr; 54(7):1818-24. PubMed ID: 8137297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
